MA50634A - Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam - Google Patents

Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam

Info

Publication number
MA50634A
MA50634A MA050634A MA50634A MA50634A MA 50634 A MA50634 A MA 50634A MA 050634 A MA050634 A MA 050634A MA 50634 A MA50634 A MA 50634A MA 50634 A MA50634 A MA 50634A
Authority
MA
Morocco
Prior art keywords
sustained
pharmaceutical compositions
compositions containing
release pharmaceutical
containing levetiracetam
Prior art date
Application number
MA050634A
Other languages
English (en)
Inventor
Michela Gallagher
Jack Lawrence James
Elsie Melsopp
Kenneth Garry Payie
Sharon Rosenzweig-Lipson
Original Assignee
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenebio Inc filed Critical Agenebio Inc
Publication of MA50634A publication Critical patent/MA50634A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050634A 2015-05-22 2016-05-20 Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam MA50634A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562165812P 2015-05-22 2015-05-22

Publications (1)

Publication Number Publication Date
MA50634A true MA50634A (fr) 2021-04-28

Family

ID=61223552

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050634A MA50634A (fr) 2015-05-22 2016-05-20 Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam

Country Status (4)

Country Link
EP (2) EP3590506A1 (fr)
DK (1) DK3297611T3 (fr)
ES (1) ES2747993T3 (fr)
MA (1) MA50634A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023243233A1 (en) * 2022-04-01 2024-11-14 Agenebio, Inc. Methods for preventing or slowing the progression of cognitive decline or impairment in subjects displaying normal cognitive performance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540129T1 (de) 2002-11-22 2012-01-15 Univ Johns Hopkins Target zur therapie kognitiver behinderungen
EP2682481A3 (fr) 2005-08-03 2014-09-17 The Johns-Hopkins University Procédés de caractérisation et de traitement de la déficience cognitive lors du vieillissement et de la maladie
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008062446A2 (fr) * 2006-09-14 2008-05-29 Alembic Limited Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments
DK2346500T3 (en) * 2008-10-16 2017-07-17 Univ Johns Hopkins Methods and compositions for improving cognitive function
KR20120055313A (ko) * 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
DE102011103270A1 (de) * 2011-05-26 2012-11-29 Stada Arzneimittel Ag Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten
EP2968220B1 (fr) * 2013-03-15 2021-05-05 Agenebio, Inc. Procédés et compositions pour améliorer la fonction cognitive

Also Published As

Publication number Publication date
EP3590506A1 (fr) 2020-01-08
ES2747993T3 (es) 2020-03-12
EP3297611B1 (fr) 2019-07-03
DK3297611T3 (da) 2019-09-02
ES2747993T8 (es) 2021-03-30
EP3297611A1 (fr) 2018-03-28

Similar Documents

Publication Publication Date Title
EP3493799A4 (fr) Composition pharmaceutique decannabis
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3655038T3 (da) Farmaceutisk sammensætning
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
EP3493798A4 (fr) Composition pharmaceutique decannabis
EP3454899C0 (fr) Composition pharmaceutique
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
EP3391459A4 (fr) Filtres à retard temporel
EP3310439A4 (fr) Compositions pharmaceutiques pour des applications anesthésiologiques
EP3603642A4 (fr) Préparation pharmaceutique
MA44212A (fr) Prégabaline à libération prolongée contrôlée
DK3583943T3 (da) Farmaceutisk sammensætning
MA49837A (fr) Compositions pharmaceutiques
EP3272362A4 (fr) Composition pharmaceutique à libération prolongée
MA44079A (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
DK3908321T3 (da) Farmaceutisk sammensætning
DK3728220T3 (da) Farmaceutiske forbindelser
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
SMT202400478T1 (it) Composizione farmaceutica
EP3646863A4 (fr) Composition pharmaceutique
EP3524250A4 (fr) Composition pharmaceutique
DK3288933T3 (da) Oxindolforbindelser og farmaceutiske sammensætninger deraf
DK3302483T3 (da) Farmaceutiske sammensætninger og anvendelse deraf
PT3949952T (pt) Composição farmacêutica
EP3705122A4 (fr) Composition pharmaceutique à libération prolongée